StreetInsider.com News Articles

Form 8-K Ocugen, Inc. For: Oct 15

Thu, 15 Oct 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20261015/27189986.html

Form 8-K Ocugen, Inc. For: Oct 13

Thu, 15 Oct 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20261015/27189041.html

Ocugen licenses OCU400 gene therapy to Roots Pharma for MENA region

Wed, 14 Oct 2026 06:30:13 -0400

Ocugen, Inc. (NASDAQ: OCGN) has signed a licensing agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding, granting exclusive rights to OCU400, a modifier gene therapy for retinitis pigmentosa (RP), across the Middle East and North Africa (MENA) region, according to a press release dated Oct. 14, 2026.

Under the terms of the agreement, Ocugen will receive an upfront license fee and potential initial development milestone payments totaling up to $4 million, potential sales milestone payments of up to $255 million, and royalties equal to 22% of OCU400 net sales generated by Roots Pharmaceutical. Ocugen will also manufacture and

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Wed, 14 Oct 2026 06:30:00 -0400

Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies
Expands access to a potential one-time gene therapy for retinitis pigmentosa in a region with high disease prevalence and substantial unmet need
Agreement includes upfront license fee and initial development payments up to $4 million, potential sales milestones up to $255 million, and royalties equaling 22% of net sales; Ocugen will manufacture and supply OCU400

MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN),

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Wed, 14 Oct 2026 06:30:00 -0400

Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies
Expands access to a potential one-time gene therapy for retinitis pigmentosa in a region with high disease prevalence and substantial unmet need
Agreement includes upfront license fee and initial development payments up to $4 million, potential sales milestones up to $255 million, and royalties equaling 22% of net sales; Ocugen will manufacture and supply OCU400

MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN),

Form 4 Ocugen, Inc. For: Oct 09 Filed by: Musunuri Shankar

Tue, 13 Oct 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20261013/27182372.html

Form 144 Ocugen, Inc. Filed by: Musunuri Shankar

Fri, 09 Oct 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20261009/27172467.html

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical development program within The Bahamas' growing longevity and regenerative-medicine sector.